Patents Examined by Kristina M Hellman
  • Patent number: 11911499
    Abstract: A minimally invasive treatment of benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. A method includes introducing a composition into the prostate to achieve a sustained release of the cytostatic or cytotoxic drug over a period of between about 14 days and 12 months.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: February 27, 2024
    Assignee: Resurge Therapeutics, Inc.
    Inventors: Olof Mikael Trollsas, John J. Stankus, Shahram Shawn Gholami
  • Patent number: 11911445
    Abstract: Pharmaceutical compositions comprising PYY (e.g., PYY(3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY(3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: February 27, 2024
    Assignee: Gila Therapeutics, Inc.
    Inventors: Andres Acosta, Thomas Vasicek, Beth Anne-Szkudlarek Brown
  • Patent number: 11913963
    Abstract: The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants.
    Type: Grant
    Filed: September 2, 2022
    Date of Patent: February 27, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mark I. Greene, Douglas B. Cines, Zheng Cai, Zhiqiang Zhu
  • Patent number: 11897937
    Abstract: SIRP1alpha-41BBL fusion proteins are provided. Accordingly, there is provided a SIRPalpha-41BBL fusion protein comprising a single amino acid linker between the SIRPalpha and the 41BBL. Also there is provided a SIRPalpha-41BBL fusion protein in a form of at least a homo-trimer. Also provided are polynucleotides and nucleic acid constructs encoding the SIRP1alpha-41BBL fusion protein, host-cells expressing the SIRP1alpha-41BBL fusion protein and methods of use thereof.
    Type: Grant
    Filed: August 12, 2021
    Date of Patent: February 13, 2024
    Assignee: KAHR Medical Ltd.
    Inventors: Noam Shani, Yosi Gozlan, Michal Dranitzki Elhalel, Edwin Bremer, Ido Kaminsky
  • Patent number: 11884709
    Abstract: Described are methods and associated uses for the treatment of resorptive bone disease using peptides comprising part of the C-terminal portion of soricidin. Also described are methods and associated uses for inhibiting osteoclast activity and/or bone resorption using the peptides.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: January 30, 2024
    Assignee: University of New Brunswick
    Inventors: Alli Murugesan, Anthony Reiman
  • Patent number: 11865160
    Abstract: Methods and compositions are provided for extending the half-life of a therapeutic agent. A modified therapeutic agent (mTA) comprises a therapeutic agent, a staple, and a half-life extending molecule. The mTAs disclosed herein may be used to treat a disease or a condition in a subject in need thereof.
    Type: Grant
    Filed: May 11, 2021
    Date of Patent: January 9, 2024
    Assignee: THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Weijun Shen, Pengyu Yang, Huafei Zou, Peter G. Schultz
  • Patent number: 11857631
    Abstract: Compositions are provided herein comprising a coacervate of a polycationic polymer, a polyanionic polymer, and platelet-rich plasma and/or serum, or a fraction or concentrate thereof. The composition is useful in wound healing. Compositions also are provided that comprise a hydrogel comprising TIMP-3; and a complex of a polycationic polymer, a polyanionic polymer, FGF-2 and SDF-1? embedded in the hydrogel, which is useful in treating a myocardial infarction.
    Type: Grant
    Filed: November 23, 2021
    Date of Patent: January 2, 2024
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Eric M. Jeffries, Yadong Wang, Daniel Long, Noah R. Johnson
  • Patent number: 11826385
    Abstract: Major histocompatibility complex-based chimeric receptors (MHC-CAR) for use in targeting autoreactive immune cells. Also provided herewith are genetically engineered immune cells expressing the MHC-CAR for use in treating autoimmune diseases such as multiple sclerosis.
    Type: Grant
    Filed: November 10, 2018
    Date of Patent: November 28, 2023
    Assignee: Jura Bio, Inc.
    Inventors: Julie Norville, Elizabeth Wood
  • Patent number: 11807674
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: November 7, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Patent number: 11795203
    Abstract: Disclosed are a protein heterodimer and the use thereof. The protein heterodimer comprises a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain comprises IL(interleukin)12a and a first factor fused to IL12a, the second polypeptide chain comprises IL12b and a second factor fused to IL12b, and the first factor and the second factor are each independently selected from a group consisting of: IL2, GMCSF(granulocyte-macrophage colony-stimulating factor), IL7, IL15, IL21 and FLT3L(FMS-like tyrosine kinase 3 ligand). The protein heterodimer can be used for treating tumors.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 24, 2023
    Inventor: Jinyu Zhang
  • Patent number: 11771735
    Abstract: An object of the present invention is to provide a composition for preventing or improving fat deposition on the liver in spite of the alcohol intake history of a level that a liver disease is not caused. The inventors found that glutathione has an effect of preventing or improving fat deposition on the liver, which is not caused by alcohol, and completed the present invention. Among nonalcoholic fat diseases, the present invention is particularly effective in an early stage of the treatment or in a case where treatment for another disease is not performed.
    Type: Grant
    Filed: November 19, 2021
    Date of Patent: October 3, 2023
    Assignees: KOHJIN LIFE SCIENCES CO., LTD., PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY, KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION, SAGA UNIVERSITY
    Inventors: Takaomi Kessoku, Atsushi Nakajima, Yoshio Sumida, Yuichiro Eguchi, Susumu Saito, Yusuke Sauchi
  • Patent number: 11773187
    Abstract: Compositions and methods are presented that allow for an enhanced immune response against a GPI-anchored tumor associated antigen by modification of the protein portion of the TAA to include a transmembrane domain and a trafficking signal that directs the modified protein to the endosomal or lysosomal compartment. Most preferably, the modified protein will no longer have a GPI anchor or GPI attachment sequence.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 3, 2023
    Assignee: NantBio, Inc.
    Inventors: Kayvan Niazi, Wael Tadros, Annie Shin
  • Patent number: 11760784
    Abstract: A pharmaceutical composition for treating an ophthalmic disease in a subject includes a peptide and a pharmaceutically acceptable excipient, wherein the peptide contains the sequence of SEQ ID NO: 1: S-X-X-A-X-Q/H-X-X-X-X-I/V-I-X-R, wherein each X is independently any amino acid.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: September 19, 2023
    Assignee: BRIM Biotechnology, Inc.
    Inventors: Frank Wen-Chi Lee, Kuanyin Karen Lin, Yeou-Ping Tsao, Tsung-Chuan Ho
  • Patent number: 11738068
    Abstract: An aqueous preparation containing a protein as an active ingredient which is stable in storage in solution and makes an injection pain reduced is provided. More specifically an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM and a protein as an active ingredient is provided. Further more specifically provided is an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM, human growth hormone as an active ingredient, a poloxamer as a non-ionic surfactant; and phenol as a isotonic agent.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: August 29, 2023
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Takashi Hanada, Junya Tani, Shinji Okabe, Yuuka Asano
  • Patent number: 11732027
    Abstract: Provided herein are peptides comprising a mutated fragment of a wild-type protease-activated receptor-2 (PAR2). The peptides comprising a hydrophobic moiety can penetrate the cell membrane and act as an antagonist of PAR2. Also provided herein are compositions and cells comprising the peptides and methods of using the peptides.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: August 22, 2023
    Assignee: Oasis Pharmaceuticals, LLC
    Inventor: Richard J. Looby
  • Patent number: 11717555
    Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a strong acid salt of a LHRH agonist or antagonist; b) a biodegradable polymer of poly(lactide-co-glycolide), wherein the ratio of lactide:glycolide of the copolymer is from 50:50 to about 100:0; and c) N-methyl-2-pyrrolidone (NMP), wherein the composition does not contain excess strong acid in addition to the strong acid used to form the salt of the LHRH agonist or antagonist. The composition, when injected, can provide a controlled release of leuprolide for a period of up to 6 months.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: August 8, 2023
    Assignee: Foresee Pharmaceuticals Co., Ltd.
    Inventors: Yuhua Li, Andrew Guarino
  • Patent number: 11717554
    Abstract: The invention provides methods for preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in a subject comprising administering an aldehyde sequestering agent so as to reduce or counter blood aldehyde buildup in the subject, thereby preventing or treating hangover symptom(s) associated with consumption of alcoholic beverage(s) in the subject.
    Type: Grant
    Filed: November 2, 2020
    Date of Patent: August 8, 2023
    Assignee: MAX R&D LLC
    Inventor: Herbert Nagasawa
  • Patent number: 11702449
    Abstract: Disclosed are improved peptides for inhibiting angiogenesis, Ac-RLYE (SEQ ID NO: 1) and R(D)LYE (SEQ ID NO: 6), and a composition for the prevention and treatment of cancers and diseases related to angiogenesis comprising the peptides as an active ingredient. A peptide for inhibiting angiogenesis is disclosed wherein the L-Arg of an N-terminal is acetylated in a peptide consisting of an amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 1). A peptide for inhibiting angiogenesis is disclosed wherein L-Arg is substituted with D-Arg in a peptide consisting of the amino acid sequence of Arg-Leu-Tyr-Glu (SEQ ID NO: 6). Methods for using a composition comprising the peptides as active ingredients for the prevention or treatment of diseases (cancer, diabetic retinopathy or senile macular degeneration) caused by excessive angiogenesis are also disclosed. The peptides have a long half-life and are excellent in VEGF-induced angiogenesis inhibitory effect.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: July 18, 2023
    Assignee: AVIXGEN INC.
    Inventors: Young Myeong Kim, Yi Yong Baek, Won Jin Park, Jeong Hun Kim, Dong Hyun Jo
  • Patent number: 11696940
    Abstract: An aqueous preparation containing a protein as an active ingredient which is stable in storage in solution and makes an injection pain reduced is provided. More specifically an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM and a protein as an active ingredient is provided. Further more specifically provided is an aqueous preparation containing a phosphate buffer at a concentration of 1 to 20 mM, human growth hormone as an active ingredient, a poloxamer as a non-ionic surfactant; and phenol as a isotonic agent.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: July 11, 2023
    Assignee: JCR Pharmaceuticals Co., Ltd.
    Inventors: Hidehito Yasukawa, Takashi Hanada, Junya Tani, Shinji Okabe, Yuuka Asano
  • Patent number: 11690895
    Abstract: Disclosed are compositions comprising an interferon-alpha binding protein and combined anti-retroviral therapy (cART). In some aspects, the interferon-alpha binding protein is B18R. In some aspects, the compositions further comprise a pharmaceutically acceptable carrier. Disclosed are methods of treating a subject with HIV associated neurogenerative disorder (HAND) comprising administering a therapeutically effective amount of B18R and cART. Disclosed are methods of reversing behavioral abnormalities in subjects having HAND comprising administering a therapeutically effective amount of B18R.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: July 4, 2023
    Assignees: MEIOGEN BIOTECHNOLOGY CORPORATION, UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: William Tyor, Rajeth Koneru, Jennifer Ward, Leonard Maroun